Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sandra J Estrada"'
Autor:
Sarah C. J. Jorgensen, Trang D. Trinh, Evan J. Zasowski, Abdalhamid M. Lagnf, Sahil Bhatia, Sarah M. Melvin, Samuel P. Simon, Joshua R. Rosenberg, Molly E. Steed, Sandra J. Estrada, Taylor Morrisette, Susan L. Davis, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 2, Pp 291-304 (2020)
Abstract Background The aim of this study was to evaluate the predictive performance of the INCREMENT-CPE (ICS), Pitt bacteremia score (PBS) and qPitt for mortality among patients treated with ceftazidime–avibactam for carbapenem-resistant Enteroba
Externí odkaz:
https://doaj.org/article/a418b4cd99f0401695ee735da7bc77bf
Autor:
Sandra J. Estrada, Rossana Zuccarello Jiménez, Eglet del R. Chirinos Sánchez, Gustavo E. Córdova Rodríguez
El artículo tuvo como objetivo determinar la importancia del factor humano en el contexto del cambio organizacional
El artículo está publicado en la revista Accounting and management, de la Corporación Universitaria Remington
El artículo está publicado en la revista Accounting and management, de la Corporación Universitaria Remington
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d101a79dc94cb376c1b70708c8c0379d
Autor:
Samuel Simon, Sahil Bhatia, Taylor Morrisette, Joshua R Rosenberg, Abdalhamid M Lagnf, Michael J. Rybak, Sarah M Melvin, Trang D Trinh, Kimberly C. Claeys, Sandra J Estrada, Molly E. Steed, Evan J Zasowski, Susan L. Davis, Sarah C J Jorgensen
Publikováno v:
Open Forum Infectious Diseases
Background We conducted this study to describe the clinical characteristics, microbiology, and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug-resistant Gram-negative (MDR-GN) infections. Methods This is a multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8dc82b1ac816d6783ab07de6d337fff
https://pubmed.ncbi.nlm.nih.gov/31890725
https://pubmed.ncbi.nlm.nih.gov/31890725
Autor:
Susan L. Davis, Sandra J Estrada, Sara Alosaimy, Sarah C J Jorgensen, Evan J Zasowski, Sahil Bhatia, Abdalhamid M Lagnf, Trang D Trinh, Molly E. Steed, Michael J. Rybak, Joshua R Rosenberg, Samuel Simon, Sarah Melvin
Publikováno v:
Open Forum Infectious Diseases
Background Ceftazidime–avibactam (CZA) is a novel cephalosporin/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) and multidrug-resistant (MDR) Pseudomonas aeruginosa (PA). Real-world experience with CZA for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b07c3d62bc9a45d50b7fad31dd62c685
http://europepmc.org/articles/PMC6809679
http://europepmc.org/articles/PMC6809679